Get the Stockscreener App
25.84
1.77%
0.45
Pacira Biosciences Inc stock is traded at $25.84, with a volume of 453.03K.
It is up +1.77% in the last 24 hours and up +15.20% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$25.39
Open:
$25.68
24h Volume:
453.03K
Relative Volume:
0.70
Market Cap:
$1.16B
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
17.82
EPS:
1.45
Net Cash Flow:
$173.19M
1W Performance:
+4.28%
1M Performance:
+15.20%
6M Performance:
+2.70%
1Y Performance:
+84.97%
1-Day Range:
$25.23
$25.94
1-Week Range:
$23.74
$25.94
52-Week Range:
$12.61
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
25.84 | 1.12B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Upgrade | Truist | Hold → Buy |
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
Pacira BioSciences Inc. stock trend forecastStock Surge & AI Based Buy and Sell Signals - Newser
Real time breakdown of Pacira BioSciences Inc. stock performanceBull Run & Target Return Focused Stock Picks - Newser
Is now a turning point for Pacira BioSciences Inc.Gold Moves & Weekly Top Gainers Alerts - Newser
Is Pacira BioSciences Inc. showing signs of accumulationMarket Risk Report & Short-Term High Return Ideas - Newser
Advanced analytics toolkit walkthrough for Pacira BioSciences Inc.Quarterly Market Review & High Return Trade Opportunity Guides - Newser
Best data tools to analyze Pacira BioSciences Inc. stockOptions Play & High Accuracy Trade Signal Alerts - Newser
Can Pacira BioSciences Inc. rally from current levelsMarket Trend Report & Intraday High Probability Setup Alerts - Newser
Does Pacira BioSciences Inc. fit your quant trading model2025 Momentum Check & Free Community Consensus Stock Picks - Newser
Can technical indicators confirm Pacira BioSciences Inc.’s reversalChart Signals & Daily Entry Point Alerts - Newser
Predicting Pacira BioSciences Inc. trend using moving averagesPortfolio Return Summary & Real-Time Buy Signal Notifications - Newser
US Bancorp DE Buys 537 Shares of Pacira BioSciences, Inc. $PCRX - Defense World
Volatility clustering patterns for Pacira BioSciences Inc.2025 Momentum Check & Reliable Entry Point Trade Alerts - Newser
Real time alert setup for Pacira BioSciences Inc. performancePortfolio Gains Summary & Low Risk High Win Rate Picks - Newser
Trend analysis for Pacira BioSciences Inc. this weekEarnings Growth Report & Safe Entry Zone Identification - Newser
How to build a dashboard for Pacira BioSciences Inc. stock2025 Technical Overview & Safe Swing Trade Setups - Newser
Is Pacira BioSciences Inc. building a consolidation baseJuly 2025 Fed Impact & Real-Time Market Trend Scan - Newser
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Earnings visualization tools for Pacira BioSciences Inc.2025 Price Action Summary & Verified Technical Signals - Newser
Order flow analysis tools used on Pacira BioSciences Inc.2025 Technical Patterns & Fast Entry High Yield Tips - Newser
Pacira BioSciences Inc. stock trendline breakdownMarket Trend Summary & Entry Point Confirmation Alerts - Newser
Signal strength of Pacira BioSciences Inc. stock in tech scannersTrade Ideas & Capital Efficient Trading Techniques - Newser
Will a bounce in Pacira BioSciences Inc. offer an exit2025 Geopolitical Influence & High Accuracy Investment Signals - Newser
Will Pacira BioSciences Inc. stock recover after recent dropJuly 2025 PreEarnings & Real-Time Volume Surge Alerts - Newser
Detecting price anomalies in Pacira BioSciences Inc. with AIJuly 2025 Market Mood & Safe Entry Momentum Tips - Newser
Is Pacira BioSciences Inc. stock a value trapJuly 2025 Closing Moves & High Yield Equity Trading Tips - kangso.co.kr
Is Pacira BioSciences Inc. stock reversal real or fakeTrade Signal Summary & Real-Time Stock Price Movement Reports - Newser
Pacira BioSciences Insiders Sold US$640k Of Shares Suggesting Hesitancy - 富途牛牛
Investors Who Lost Money with Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Should Contact the Shareholders Foundation in Connection with Lawsuit - Newswire.com
Natixis Advisors LLC Invests $327,000 in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):